NEWSROOM | Galderma

Galderma to showcase latest updates from its broad, innovative and leading dermatology portfolio at the 2024 American Academy of Dermatology annual meeting

Galderma announces regulatory filing acceptance for nemolizumab in prurigo nodularis and atopic dermatitis in the U.S. and EU

Making an impact

Galderma takes the ‘Face of Cetaphil®’ to the runway at New York City fashion week

Galderma launches ‘NEXT’, a ground-breaking trend report that unveils the future of aesthetics

Galderma celebrates 25 years of excellence in biostimulation with Sculptra® at the 2024 IMCAS

The remarkable journey of Restylane, from the lab to the patient

IMCAS 2024: Galderma to present latest updates from its unparalleled aesthetics portfolio reinforcing its leadership position

IMCAS 2024: Galderma’s scientific presentations

Galderma announces regulatory approval for Restylane® SHAYPE™, a new hyaluronic acid injectable designed for augmenting the chin region

Collaborative growth

TOXINS 2024: Galderma’s phase III RelabotulinumtoxinA results demonstrate positive efficacy and long duration of effect when treating frown lines and crow’s feet simultaneously